Angiotensin Converting Enzymes (ACE) Inhibitors Market gaining significant growth on the account of increasing prevalence of hypertension around the globe

North America is expected to lead the global angiotensin converting enzymes (ACE) inhibitors market and this is due to the fact that the region is accounted for the increasing approval activities by the U.S. Food and Drug Administration (FDA). Also, the region is accounted for the high prevalence rate of hypertension. According to the Centers for Disease Control and Prevention, high blood pressure was a primary or contributing cause of death for more than 494,873 people in the United States in 2018

The growing prevalence of hypertension around the globe is propelling the growth of the angiotensin converting enzyme (ACE) inhibitors market. According to World Health Organization’s (WHO) report, in 2018, around 207 million people including 112 million men and 95 million women suffer from hypertension, annually in India. Also, a growing number of research and development activities for the improvement of cardiovascular functions during pregnancy is again fostering the growth of the angiotensin converting enzymes (ACE) inhibitors market. For example, in September 2018, Manchester University NHS Foundation Trust initiated a clinical Phase II study of Enalapril Maleate for the pre-eclampsia condition. This study is for the study of drug safety and efficacy on the patients. Pre-eclampsia condition is a pregnancy complication characterized by high blood pressure. It has various signs and symptoms including proteinuria, upper abdominal pain, and shortness of breath.

Growing focus on increasing the awareness regarding hypertension among people will have a positive impact on the angiotensin-converting enzymes (ACE) inhibitors market. For instance, in May 2018, the Indian Council of Medical Research (ICMR) organized an awareness campaign on hypertension in collaboration with the Public Health Foundation of India. According to ICMR, around 10.8% of deaths annually are caused by hypertension in India.

Angiotensin-Converting Enzymes Inhibitors are a drug that is designed to block the action of the angiotensin II enzyme. The enzyme, angiotensin I, is responsible for the relaxation and constriction of your blood vessels. When this occurs it causes arteries to narrow, the heart to increase itsricular output, and produce increased amounts of 'nestin' which are waste products from the broken down muscle and connective tissue. This all occurs because the angiotensin I enzyme blocks the nerve impulses that cause the muscle fibers to constrict and widen. The inhibitors will then allow the coronary vasculature to return to its previous state.

Key players operating in the angiotensin-converting enzymes (ACE) inhibitors market include Pfizer, Inc., AstraZeneca Pharmaceutical Company, Novartis AG, Daiichi Sankyo Company, Ltd., United Therapeutics Corporation, Sanofi S.A., Johnson & Johnson Services, Inc., Merck KGaA, Takeda Pharmaceutical Company, and Bayer AG.